Mehr »
Montag, 05.12.2022 Börsentäglich über 12.000 News von 678 internationalen Medien
Vor Ver-10-fachung? Jetzt schon in den Lithium-Star 2023 investieren?



24 h / 7 T
7 Tage



24 h / 7 T
7 Tage














Erweiterte Suche
PR Newswire
343 Leser
Artikel bewerten:

Dramatic Rise in Stem Cell Therapy Use in 2012

PHILADELPHIA, Nov. 26, 2012 /PRNewswire/ --RRY Publications LLC today announced that the use of stem cell therapies in 2012 significantly exceeded forecasts which were originally presented at the February 2012 New York Stem Cell Summit. Said Robin Young, stem cell industry analyst and host of the New York meeting: "The range and scope of stem cell therapeutic use in the United States grew much faster than we'd forecasted earlier this year. Virtually all of the increases we're seeing are for adult stem cell therapies and, in particular, the use by physicians of both allograft and autologous stem cell products. It would not be an exaggeration to call this unexpected and remarkable growth."

Mr. Young's revised forecast of stem cell commercialization revenues for 2013-2020 will be presented at the February meeting in New York.

The companies, scientists and physicians that are at the forefront of this remarkable increase in stem cell therapeutic use will be presenting at the 8th Annual New York Stem Cell Summit. Listed below is the preliminary lineup of presenters for the 8th Annual Stem Cell Summit.

The Stem Cell Summit, an intensive one-day event, allows attendees to learn about the latest developments in the stem cell marketplace, evaluate the groundbreaking stem cell products physicians are using today, and discover the growing market potential in terms of revenues. For 2013, the Summit will feature 30+ presenters, a research review and debate session, and a special track on expanding the range of stem cell therapies.

The 8th Annual Stem Cell Summit will take place on Feb. 19, 2013, at Bridgewaters in the heart of New York City's historic South Street Seaport. The preliminary roster of companies featured will include representatives from 2012 presenters and new 2013 presenters.

Aastrom Biosciences, Inc.

Advanced Cell Technology

Aldagen, Inc.

AllCells, LLC.

Aruna Biomedical, Inc.

Athersys, Inc.

Bioheart Inc.

BioLife Solutions

BioTime Inc./Embryome Sciences, Inc.

Brainstorm Cell Therapeutics

Case Western Reserve University

CellCyte Genetics Corp.

Celgene Corporation

Celtigen Therapeutics

Cord Blood America, Inc. (CBAI.OB)

Core Dynamics Ltd.

Cytori Therapeutics, Inc.

Gamida Cell Ltd.

Garnet BioTherapeutics, Inc.

Histogen Inc

INCELL Corporation LLC

International Stem Cell Corporation

Lifenet Health

Lonza Group Ltd.

Medistem Inc.

Mesoblast Limited

MultiCell Technologies [MCET]

Neostem, Inc.


Opexa Therapeutics, Inc.

Osiris Therapeutics, Inc.

Parcell Labs

Pathfinder Cell Therapy

Pervasis Therapeutics, Inc.

Pluristem Therapeutics, Inc.

Prochon Biotech, Ltd.

Progenitor Cell Therapy, LLC

Stem Cell Innovations

Stem Cell Therapeutics (SCTPF)

StemCells Inc.

TiGenix NV

Tissue Genesis, Inc.


Vet-Stem, Inc.


WuXi AppTec

In addition to the company and product overviews, Robin Young, president of RRY Publications and the organizer of the annual Stem Cell Summit, will deliver his updated 10-year market forecast for the industry.

8th Annual New York Stem Cell Summit Facts at a Glance


Largest Gathering of Stem Cell Company Executives, Scientists, Investors, and Physicians


February 19, 2013



11 Fulton Street

New York City


The Stem Cell Summit is organized by RRY Publications LLC


$950 through November 2012

$1,500 Registration (February 1, 2013 - February 19, 2013 and onsite)


For more information on presentation or sponsorship opportunities, call Bharathi Kavalipati at

610-260-6462 or send an email to

Additional information, including attendee registration details, is available at


Suzanne Kirchner

RRY Publications LLC


SOURCE RRY Publications LLC

Kostenloser Wertpapierhandel auf
© 2012 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.